ReviewClinical microbiology reviews2002
Innate immunity to Mycobacterium tuberculosis.
Review in Clinical microbiology reviews, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
208 citing papers in PubMed, 589 citations in OpenAlex.
- BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial.JCI insight · 2017Trial
- Bacterial load and transforming growth factor-beta: Predicting the extent of lung damage in pulmonary tuberculosis patients.World journal of experimental medicine · 2026Article
- VEGFR Blockade ReducesCells · 2026Article
- Protein Kinase C δ: a critical hub regulating macrophage immunomodulatory functions duringbioRxiv : the preprint server for biology · 2025Article
- Isoniazid preventive therapy modulates Mycobacterium tuberculosis-specific T-cell responses in individuals with latent tuberculosis and type 2 diabetes.Scientific reports · 2025Article
- Association between advanced lung cancer inflammation index and acute gouty arthritis in Dalian, China: a cross-sectional study.Frontiers in nutrition · 2025Article
- Model systems to studyFrontiers in cellular and infection microbiology · 2025Review
- Deciphering the functional roles of PE18 and PPE26 proteins in modulatingFrontiers in immunology · 2025Article
- Chronic hyperglycemia impairs anti-microbial function of macrophages in response to Mycobacterium tuberculosis infection.Immunologic research · 2024Article
- Article
- Biosensors; nanomaterial-based methods in diagnosing ofJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Model-based impact evaluation of new tuberculosis vaccines in aging populations under different modeling scenarios: the case of China.Frontiers in public health · 2024Article
- Polymorphisms in Immune Genes and Their Association with Tuberculosis Susceptibility: An Analysis of the African Population.The application of clinical genetics · 2024Review
- Revisiting the role of mesenchymal stem cells in tuberculosis and other infectious diseases.Cellular & molecular immunology · 2023Review
- Role of B Cells in Mycobacterium Tuberculosis Infection.Vaccines · 2023Review
- Analysis of the noncoding RNA regulatory networks of H37Rv- and H37Rv△1759c-infected macrophages.Frontiers in microbiology · 2023Article
- Investigating the comorbidity of COPD and tuberculosis, a computational study.Frontiers in systems biology · 2023Article
- Malaria and tuberculosis co-infection-a review.Oxford open immunology · 2023Review
- Remembering St. Louis individual-structural violence and acute bacterial infections in a historical anatomical collection.Communications biology · 2022Article
- CD44 receptor targeted nanoparticles augment immunity against tuberculosis in mice.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
148 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The different manifestations of infection with Mycobacterium tuberculosis reflect the balance between the bacillus and host defense mechanisms. Traditionally, protective immunity to tuberculosis has been ascribed to T-cell-mediated immunity, with CD4(+) T cells playing a crucial role. Recent immunological and genetic studies support the long-standing notion that innate immunity is also relevant in tuberculosis. In this review, emphasis is on these natural, innate host defense mechanisms, referring to experimental data (e.g., studies in gene knockout mice) and epidemiological, immunological, and genetic studies in human tuberculosis. The first step in the innate host defense is cellular uptake of M. tuberculosis, which involves different cellular receptors and humoral factors. Toll-like receptors seem to play a crucial role in immune recognition of M. tuberculosis, which is the next step. The subsequent inflammatory response is regulated by production of pro- and anti-inflammatory cytokines and chemokines. Different natural effector mechanisms for killing of M. tuberculosis have now been identified. Finally, the innate host response is necessary for induction of adaptive immunity to M. tuberculosis. These basic mechanisms augment our understanding of disease pathogenesis and clinical course and will be of help in designing adjunctive treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.